Management of Invasive Fungal Disease in Neonates and Children

Laura Ferreras-Antolín, Mike Sharland, Adilia Warris (Corresponding Author)

Research output: Contribution to journalArticle

Abstract

Invasive fungal diseases (IFD) are an important cause of morbidity and mortality in premature neonates and immunocompromised pediatric patients. Their diagnostic and therapeutic management remains a challenge. A nationwide survey was conducted among 13 of the largest pediatric units in the United Kingdom, to obtain insight in the current management of IFD in neonates and children. All responding centers were tertiary teaching centers. The use of fungal diagnostic tools and imaging modalities varied among centers. Antifungal prophylaxis was prescribed in most centers for extreme-low birth weight (LBW) infants and high-risk hemato-oncologic patients, but with a huge variety in antifungals given. An empirical treatment was favored by most centers in case of febrile neutropenia. First line therapy for candidemia consists of either fluconazole or liposomal amphotericin B, with voriconazole being first-line therapy for invasive aspergillosis. Disseminated invasive aspergillosis was most often mentioned as a reason to prescribe combination antifungal therapy. In conclusion, this survey reinforces the fact that there are still important aspects in the management of pediatric IFD which should ideally be addressed in pediatric clinical trials. Attention needs to be given the knowledge gaps as observed in the results of our survey to optimize the management of IFD in children and neonates.

Original languageEnglish
Pages (from-to)S2-S6
Number of pages5
JournalThe Pediatric infectious disease journal
Volume38
Issue number6S Suppl 1
DOIs
Publication statusPublished - 1 Jun 2019

Fingerprint

Mycoses
Newborn Infant
Pediatrics
Aspergillosis
Candidemia
Therapeutics
Febrile Neutropenia
Premature Mortality
Fluconazole
Immunocompromised Host
Low Birth Weight Infant
Diagnostic Imaging
Teaching
Clinical Trials
Morbidity
Surveys and Questionnaires

Keywords

  • invasive fungal disease
  • invasive aspergillosis
  • candidemia
  • antifungal therapy
  • fungal diagnostics
  • DIAGNOSIS
  • INFECTIONS
  • 2016 UPDATE
  • NEUTROPENIC PATIENTS
  • PERSISTENT FEVER
  • LIPOSOMAL AMPHOTERICIN-B
  • ASPERGILLOSIS
  • PEDIATRIC-PATIENTS
  • CLINICAL-PRACTICE GUIDELINE
  • ANTIFUNGAL THERAPY

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pediatrics, Perinatology, and Child Health

Cite this

Management of Invasive Fungal Disease in Neonates and Children. / Ferreras-Antolín, Laura; Sharland, Mike; Warris, Adilia (Corresponding Author).

In: The Pediatric infectious disease journal, Vol. 38, No. 6S Suppl 1, 01.06.2019, p. S2-S6.

Research output: Contribution to journalArticle

Ferreras-Antolín, Laura ; Sharland, Mike ; Warris, Adilia. / Management of Invasive Fungal Disease in Neonates and Children. In: The Pediatric infectious disease journal. 2019 ; Vol. 38, No. 6S Suppl 1. pp. S2-S6.
@article{9da934f5d6764cca9abda0cd32be9012,
title = "Management of Invasive Fungal Disease in Neonates and Children",
abstract = "Invasive fungal diseases (IFD) are an important cause of morbidity and mortality in premature neonates and immunocompromised pediatric patients. Their diagnostic and therapeutic management remains a challenge. A nationwide survey was conducted among 13 of the largest pediatric units in the United Kingdom, to obtain insight in the current management of IFD in neonates and children. All responding centers were tertiary teaching centers. The use of fungal diagnostic tools and imaging modalities varied among centers. Antifungal prophylaxis was prescribed in most centers for extreme-low birth weight (LBW) infants and high-risk hemato-oncologic patients, but with a huge variety in antifungals given. An empirical treatment was favored by most centers in case of febrile neutropenia. First line therapy for candidemia consists of either fluconazole or liposomal amphotericin B, with voriconazole being first-line therapy for invasive aspergillosis. Disseminated invasive aspergillosis was most often mentioned as a reason to prescribe combination antifungal therapy. In conclusion, this survey reinforces the fact that there are still important aspects in the management of pediatric IFD which should ideally be addressed in pediatric clinical trials. Attention needs to be given the knowledge gaps as observed in the results of our survey to optimize the management of IFD in children and neonates.",
keywords = "invasive fungal disease, invasive aspergillosis, candidemia, antifungal therapy, fungal diagnostics, DIAGNOSIS, INFECTIONS, 2016 UPDATE, NEUTROPENIC PATIENTS, PERSISTENT FEVER, LIPOSOMAL AMPHOTERICIN-B, ASPERGILLOSIS, PEDIATRIC-PATIENTS, CLINICAL-PRACTICE GUIDELINE, ANTIFUNGAL THERAPY",
author = "Laura Ferreras-Antol{\'i}n and Mike Sharland and Adilia Warris",
note = "The work presented in this manuscript was supported by a Gilead UK Clinical Fellowship Award. A.W. is supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen. Deposited in PubMed Central immediately upon publication: http://www.wkopenhealth.com/Institutions.html",
year = "2019",
month = "6",
day = "1",
doi = "10.1097/INF.0000000000002317",
language = "English",
volume = "38",
pages = "S2--S6",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "6S Suppl 1",

}

TY - JOUR

T1 - Management of Invasive Fungal Disease in Neonates and Children

AU - Ferreras-Antolín, Laura

AU - Sharland, Mike

AU - Warris, Adilia

N1 - The work presented in this manuscript was supported by a Gilead UK Clinical Fellowship Award. A.W. is supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen. Deposited in PubMed Central immediately upon publication: http://www.wkopenhealth.com/Institutions.html

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Invasive fungal diseases (IFD) are an important cause of morbidity and mortality in premature neonates and immunocompromised pediatric patients. Their diagnostic and therapeutic management remains a challenge. A nationwide survey was conducted among 13 of the largest pediatric units in the United Kingdom, to obtain insight in the current management of IFD in neonates and children. All responding centers were tertiary teaching centers. The use of fungal diagnostic tools and imaging modalities varied among centers. Antifungal prophylaxis was prescribed in most centers for extreme-low birth weight (LBW) infants and high-risk hemato-oncologic patients, but with a huge variety in antifungals given. An empirical treatment was favored by most centers in case of febrile neutropenia. First line therapy for candidemia consists of either fluconazole or liposomal amphotericin B, with voriconazole being first-line therapy for invasive aspergillosis. Disseminated invasive aspergillosis was most often mentioned as a reason to prescribe combination antifungal therapy. In conclusion, this survey reinforces the fact that there are still important aspects in the management of pediatric IFD which should ideally be addressed in pediatric clinical trials. Attention needs to be given the knowledge gaps as observed in the results of our survey to optimize the management of IFD in children and neonates.

AB - Invasive fungal diseases (IFD) are an important cause of morbidity and mortality in premature neonates and immunocompromised pediatric patients. Their diagnostic and therapeutic management remains a challenge. A nationwide survey was conducted among 13 of the largest pediatric units in the United Kingdom, to obtain insight in the current management of IFD in neonates and children. All responding centers were tertiary teaching centers. The use of fungal diagnostic tools and imaging modalities varied among centers. Antifungal prophylaxis was prescribed in most centers for extreme-low birth weight (LBW) infants and high-risk hemato-oncologic patients, but with a huge variety in antifungals given. An empirical treatment was favored by most centers in case of febrile neutropenia. First line therapy for candidemia consists of either fluconazole or liposomal amphotericin B, with voriconazole being first-line therapy for invasive aspergillosis. Disseminated invasive aspergillosis was most often mentioned as a reason to prescribe combination antifungal therapy. In conclusion, this survey reinforces the fact that there are still important aspects in the management of pediatric IFD which should ideally be addressed in pediatric clinical trials. Attention needs to be given the knowledge gaps as observed in the results of our survey to optimize the management of IFD in children and neonates.

KW - invasive fungal disease

KW - invasive aspergillosis

KW - candidemia

KW - antifungal therapy

KW - fungal diagnostics

KW - DIAGNOSIS

KW - INFECTIONS

KW - 2016 UPDATE

KW - NEUTROPENIC PATIENTS

KW - PERSISTENT FEVER

KW - LIPOSOMAL AMPHOTERICIN-B

KW - ASPERGILLOSIS

KW - PEDIATRIC-PATIENTS

KW - CLINICAL-PRACTICE GUIDELINE

KW - ANTIFUNGAL THERAPY

UR - http://www.scopus.com/inward/record.url?scp=85068214084&partnerID=8YFLogxK

UR - https://journals.lww.com/pidj/fulltext/2019/06001/Management_of_Invasive_Fungal_Disease_in_Neonates.2.aspx#pdf-link

U2 - 10.1097/INF.0000000000002317

DO - 10.1097/INF.0000000000002317

M3 - Article

VL - 38

SP - S2-S6

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 6S Suppl 1

ER -